23andMe, Inc. Is Still Under FDA Review, But Here's Their Next Move

Following a suspension by the FDA, personal genomics company 23andMe put their CEO on stage during a popular annual conference in Austin, Texas, to address brewing controversy. 23andMe used to offer a genetic "spit test" for $99. You'd spit into a tube, mail it in, and the company would screen part of your DNA for traits tied to ancestry, inheritable diseases, and more. The company let users privately access their results online--including disease risk information--yet 23andMe never billed itself as a medical product or service. The FDA didn't like this and, late last year, told the company to cease processing the tests, pending a formal review.

Hey, check out all the engineering jobs. Post your resume today!